The Combination Chemotherapy of SIRIOX as First- or Second-Line Chemotherapy for Pancreatic Cancer
Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
Pancreatic cancer represents the most lethal of the common malignancies with a 5-year
survival rate of less than 5%. For patients who are eligible for potentially curative
resection, despite mortality and morbidity rates after surgery have improved, the recurrence
rate is up to 85% within 2 years. FOLFIRINOX (fluoropyrimidine/leucovorin plus irinotecan and
oxaliplatin) has been proved to significantly improve the prognosis and is recommended as
first line treatment in patients with advanced pancreatic cancer. However, the regimen is
limited due to the severe adverse effects. Thus, the investigators replaced 5-FU and
leucovorin in the FOLFIRINOX regimen with oral S-1, a new oral fluoropyrimidine derivative
which was proved to be the well-tolerated and effectively in large III phase randomized
clinical trial, to form the SIRIOX regimen. A phase I clinical trial from Japan found that
SOXIRI (S-1, oxaliplatin and irinotecan) works in patients with advanced pancreatic cancer.
In this study, the researchers intend to investigate the activity and safety of the
combination of this regimen in patients with advanced pancreatic cancer, as first- or
second-line chemotherapy.